Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLR1A | O95602 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47601 | 0.84 | KDM4E (0.39) | KDM4EATMOPRM1DRD3DRD4 | |
| SCHEMBL47640 | 0.82 | OPRM1 (0.39) | KDM4EATMOPRM1DRD3DRD4 | |
| SCHEMBL47674 | 0.81 | CHRM2 (0.40) | POLR1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL47654 | 0.81 | CHRM2 (0.40) | POLR1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12305556 | 0.81 | ALDH1A1 (0.48) | KDM4EATMOPRM1DRD3DRD4 | |
| SCHEMBL47638 | 0.80 | CHRM2 (0.40) | KDM4EATMPOLR1AALDH1A1CHRM2 | |
| SCHEMBL47635 | 0.80 | CYP2C19 (0.40) | KDM4EATMPOLR1AALDH1A1CHRM2 | |
| SCHEMBL47643 | 0.79 | KDM4E (0.40) | KDM4EATMOPRM1DRD3DRD4 | |
| SCHEMBL10269519 | 0.78 | KMT2A (0.63) | TP53POLR1AKMT2AHPGDALDH1A1 | |
| SCHEMBL12334145 | 0.77 | UTS2R (0.48) | TP53POLR1AKMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
| US-9511122-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-12-06 | — | — | US | disclosed |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-9272048-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | Ascendis Phama A/S (DK) | 2014-10-30 | — | — | US | disclosed |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-08-28 | — | — | US | disclosed |
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ABCB11, SLCO1B1, SLC7A1 | KDM4E 3887/4885ATM 4841/4885OPRM1 311/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | KDM4E 4186/4885ATM 3069/4885OPRM1 4549/4885 |
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | GHRHR, GHSR, GCG | KDM4E 2150/4885ATM 3497/4885OPRM1 4177/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KDM4E 1756/4885ATM 2090/4885OPRM1 3092/4885 |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ADAMTS13, ADAMTS5, TNF | KDM4E 4331/4885ATM 4246/4885OPRM1 1706/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | KDM4E 2150/4885ATM 3497/4885OPRM1 4177/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KDM4E 1446/4885ATM 4184/4885OPRM1 696/4885 |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | GHRHR, GHITM, GHSR | KDM4E 3989/4885ATM 3471/4885OPRM1 3902/4885 |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | KDM4E 3989/4885ATM 3471/4885OPRM1 3902/4885 |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | P4HA1, CYP8B1, PAH | KDM4E 3467/4885ATM 4290/4885OPRM1 143/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | KDM4E 1429/4885ATM 4195/4885OPRM1 702/4885 |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | SLC6A7, PRAP1, PELP1 | KDM4E 4594/4885ATM 2145/4885OPRM1 1599/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | KDM4E 2150/4885ATM 3497/4885OPRM1 4177/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | KDM4E 4186/4885ATM 3069/4885OPRM1 4549/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | KDM4E 4661/4885ATM 4595/4885OPRM1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.